NIKA · Nika Pharmaceuticals, Inc
$0.41
At close · Aug 26
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 10, 2026
Market Cap
$431.19M
Shares
1.05B
NIKA metrics
36 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.41
Market cap
$431.19M
Price action
19 metricsPrice change (1W)
-2.4%
Price change (30D)
-19.6%
Price change (3M)
+103.0%
Price change (6M)
-45.7%
Price change (YTD)
+7.9%
Price change (1Y)
-56.7%
Trailing year
Price change (5Y)
—
52-week high
$0.96
52-week low
$0.20
Change from 52-week high
-57.2%
Change from 52-week low
+103.0%
Annualized volatility
—
Beta
—
RSI (14D)
47.5
Price vs SMA 50
-10.2%
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
1.05B
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2,768,060.2×
reciprocal yield 0.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
2,764,055.0×
reciprocal yield 0.0%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
0.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$78,125
Net income (TTM)
−$78,125
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$156
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-785.8%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$337,692
Latest balance sheet
Cash & equivalents
$2,932
Total assets
$9,942
Total debt
$340,624
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$69,144
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
19 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged